PE20080188A1 - Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol - Google Patents

Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol

Info

Publication number
PE20080188A1
PE20080188A1 PE2007000463A PE2007000463A PE20080188A1 PE 20080188 A1 PE20080188 A1 PE 20080188A1 PE 2007000463 A PE2007000463 A PE 2007000463A PE 2007000463 A PE2007000463 A PE 2007000463A PE 20080188 A1 PE20080188 A1 PE 20080188A1
Authority
PE
Peru
Prior art keywords
reduce
ppar
acetic acid
benzoazepine
oxy
Prior art date
Application number
PE2007000463A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Yan Zhang
Lan Shen
Songfeng Lu
Keith T Demarest
Patricia Pelton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38610435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080188A1 publication Critical patent/PE20080188A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X ES UN ENLACE COVALENTE, O, S; R1 y R2 SON CADA UNO H, ALQUILO C1-C8 SUSTITUIDO O NO O FORMAN JUNTO AL ATOMO DE CARBONO CICLOALQUILO C3-C7; R3 ES H; R4 y R5 SON CADA UNO H, HALO, ALQUILO C1-C8, ENTRE OTROS; R6 y R7 SON CADA UNO H, HALO, ALQUILO C1-C3, ALCOXI C1-C3, ENTRE OTROS; n ES 1; Q ES 1,2-TIAZOL, TIAZOL, TIOFENO, 3-METILTIAZOL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO {3-[3-(4-TRIFLUOROMETIL-FENIL)ISOTIAZOL-5-ILMETIL]-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-ILOXI)-ACETICO; ACIDO 2-METIL-2-{3-[3-(4-TRIFLUOROMETIL-FENIL)-ISOTIAZOL-5-ILMETIL} 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-ILOXI}-PROPIONICO; ENTRE OTROS. SE REFIERE TAMBIEN UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON AGONISTAS DE RECEPTORES ACTIVADOS POR EL PROLIFERADOR DE PEROXISOMA (PPAR), UTILES EN EL TRATAMIENTO DE NEUROPATIA, RETINOPATIA, NEFROPATIA, CATARATAS, ATEROSCLEROSIS Y OTROS TRASTORNOS RELACIONADOS
PE2007000463A 2006-04-18 2007-04-16 Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol PE20080188A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79300106P 2006-04-18 2006-04-18

Publications (1)

Publication Number Publication Date
PE20080188A1 true PE20080188A1 (es) 2008-03-10

Family

ID=38610435

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000463A PE20080188A1 (es) 2006-04-18 2007-04-16 Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol

Country Status (30)

Country Link
US (2) US7678786B2 (es)
EP (1) EP2010289B1 (es)
JP (1) JP5232771B2 (es)
KR (1) KR101472370B1 (es)
CN (1) CN101479008B (es)
AR (1) AR060489A1 (es)
AT (1) ATE535282T1 (es)
AU (1) AU2007237928B2 (es)
BR (1) BRPI0711695A2 (es)
CA (1) CA2649700C (es)
CO (1) CO6160296A2 (es)
CR (1) CR10447A (es)
EA (1) EA016583B1 (es)
EC (1) ECSP088841A (es)
ES (1) ES2375754T3 (es)
GT (1) GT200800226A (es)
HK (1) HK1124797A1 (es)
HN (1) HN2008001559A (es)
IL (1) IL194850A (es)
JO (1) JO3444B1 (es)
MX (1) MX2008013534A (es)
MY (1) MY144637A (es)
NO (1) NO344334B1 (es)
NZ (1) NZ571998A (es)
PE (1) PE20080188A1 (es)
TW (1) TWI404712B (es)
UA (1) UA96150C2 (es)
UY (1) UY30288A1 (es)
WO (1) WO2007121432A2 (es)
ZA (1) ZA200809790B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP3090739A1 (en) * 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions composed of naproxen sodium and nizatidine
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102112440A (zh) 2008-05-30 2011-06-29 武田药品工业株式会社 杂环化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9051290B2 (en) 2010-04-28 2015-06-09 Leo Pharma A/S Biaryl phosphodiesterase inhibitors
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2603032T3 (es) 2010-07-15 2017-02-23 Bayer Intellectual Property Gmbh Compuestos de 3-piridil-heteroarilcarboxamida como pesticidas
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2817007A1 (en) 2012-02-24 2014-12-31 Nestec S.A. Peltatin for the treatment of chronic inflammatory disorders
WO2013124381A1 (en) 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of metabolic disorders
WO2013124382A1 (en) 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of cardiovascular disorders
US9695137B2 (en) * 2013-03-14 2017-07-04 The University Of Toledo Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same
WO2016057322A1 (en) * 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
US20210145775A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) * 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
DE3366107D1 (en) 1982-09-30 1986-10-16 Merck Frosst Canada Inc Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) * 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
WO1997027847A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method of treating diabetes and related disease states
ES2202582T3 (es) 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
JP4427825B2 (ja) 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
NZ529351A (en) 2001-06-07 2006-01-27 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
CN1537093A (zh) 2001-07-30 2004-10-13 ŵ��Ų�ڿ˹�˾ 新乙烯基羧酸衍生物以及它们作为抗糖尿病等药物的用途
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
CA2458621A1 (en) * 2001-08-29 2003-03-06 Warner-Lambert Company Llc Oral antidiabetic agents
MXPA04003398A (es) * 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
CN1688540A (zh) 2002-09-05 2005-10-26 诺沃挪第克公司 新颖的乙烯基羧酸衍生物以及它们的治疗用途
PL376718A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki, ich wytwarzanie i stosowanie
KR20050055790A (ko) 2002-10-28 2005-06-13 노보 노르디스크 에이/에스 Ｐｐａｒ 매개 질환의 치료에 유용한 신규 화합물
WO2004092131A1 (en) * 2003-01-06 2004-10-28 Eli Lilly And Company Indole derivatives as ppar modulators
US7384965B2 (en) * 2003-01-06 2008-06-10 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
ATE553185T1 (de) 2003-02-14 2012-04-15 Biogen Idec Inc Expressionskassette und vektor zur transienten oder stabilen expression exogener moleküle
PA8594401A1 (es) * 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005019151A1 (en) * 2003-08-20 2005-03-03 Eli Lilly And Company Ppar modulators
EP1670744B9 (en) * 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
JP4928941B2 (ja) * 2003-09-19 2012-05-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
JP2007527416A (ja) * 2003-10-31 2007-09-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
ES2342082T3 (es) 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997619B (zh) * 2004-07-01 2010-08-25 霍夫曼-拉罗奇有限公司 包含乙炔基的苯基衍生物
JP2008512408A (ja) * 2004-09-11 2008-04-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ７−アザインドール類、それらの製造方法及びそれらの医薬としての使用
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
MY145712A (en) * 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
AU2007210076A1 (en) * 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as PPAR modulators
GB0618963D0 (en) * 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
AU2007237928A1 (en) 2007-10-25
TW200813003A (en) 2008-03-16
US20100120748A1 (en) 2010-05-13
TWI404712B (zh) 2013-08-11
BRPI0711695A2 (pt) 2011-12-06
JP2009534402A (ja) 2009-09-24
NO344334B1 (no) 2019-11-04
EA200870445A1 (ru) 2009-04-28
US20070244094A1 (en) 2007-10-18
EP2010289B1 (en) 2011-11-30
ATE535282T1 (de) 2011-12-15
ZA200809790B (en) 2009-12-30
CA2649700A1 (en) 2007-10-25
JP5232771B2 (ja) 2013-07-10
ES2375754T3 (es) 2012-03-06
NO20084847L (no) 2008-12-16
IL194850A0 (en) 2009-08-03
CN101479008B (zh) 2013-07-17
HK1124797A1 (en) 2009-07-24
MY144637A (en) 2011-10-14
EP2010289A2 (en) 2009-01-07
WO2007121432A2 (en) 2007-10-25
AU2007237928B2 (en) 2011-11-17
HN2008001559A (es) 2012-01-17
AR060489A1 (es) 2008-06-18
CR10447A (es) 2009-02-23
CN101479008A (zh) 2009-07-08
US7678786B2 (en) 2010-03-16
WO2007121432A3 (en) 2008-10-30
GT200800226A (es) 2009-03-13
US8633184B2 (en) 2014-01-21
ECSP088841A (es) 2008-11-27
UY30288A1 (es) 2007-08-31
EP2010289A4 (en) 2010-05-26
KR20080109933A (ko) 2008-12-17
CO6160296A2 (es) 2010-05-20
EA016583B1 (ru) 2012-06-29
NZ571998A (en) 2011-08-26
KR101472370B1 (ko) 2014-12-15
CA2649700C (en) 2015-04-14
JO3444B1 (ar) 2019-10-20
MX2008013534A (es) 2008-10-29
IL194850A (en) 2013-04-30
UA96150C2 (ru) 2011-10-10

Similar Documents

Publication Publication Date Title
PE20080188A1 (es) Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
PE20091901A1 (es) Activadores de glucoquinasa
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20121440A1 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20050417A1 (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20121522A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20091222A1 (es) Bifenilo sustituidos como moduladores del receptor gpra40
PE20070545A1 (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
PE20060415A1 (es) Compuestos heteroaril- y fenilsulfamoilo sustituidos
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
PE20120764A1 (es) Derivados de isotiazolo-pirimidindiona como moduladores de trpa1
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
NZ629630A (en) Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
PE20121280A1 (es) Derivados de (tio)morfolina como moduladores de s1p

Legal Events

Date Code Title Description
FG Grant, registration